Browsing by Author "Korkmaz, T."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey
    (Elsevier, 2018-10-01) Kılıçkap, S.; Öztürk, A.; Karadurmuş, N.; Korkmaz, T.; Yumuk, P.; Cicin, I.; Paydaş, S.; Cilbir, E.; Sakalar, T.; Uysal, M.; Uskent, N.; Demir, N.; Sakin, A.; Turhal, N.; Keskin, S.; Tural, D.; Eralp, Y.; Basal, F.; Yaşar, H.; Sendur, M. A.; Demirci, U.; Çubukcu, Erdem; Karaağaç, M.; Karaca, S.; Tatlı, A.; Yetişyiğit, T.; Urvay, S.; Gürsoy, P.; Uluc, B. Oyan; Turna, Z.; Küçükoner, M.; Çlmez, O.; Çabuk, D.; Şeker, M.; Ünal, O.; Meydan, N.; Okutur, S.; Tunalı, D.; ÇUBUKÇU, ERDEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi; JGT-4101-2023
  • No Thumbnail Available
    Publication
    Impact of systemic inflammatory markers in patients with alk -positive non-small cell lung cancer treated with crizotinib
    (Elsevier, 2023-11-01) Ölmez, O. F.; Bilici, A.; Gürsoy, P.; Sakin, A.; Korkmaz, T.; Çil, I.; Çakar, B.; Menekse, S.; Demir, T.; Acıkgöz, O.; Hamdard, J.; Çubukcu, Erdem; ÇUBUKÇU, ERDEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.
    Objectives: To evaluate the prognostic utility of inflammation-based prognostic scores in patients with ALK-positive metastatic or non-resectable non-small-cell lung cancer (NSCLC) treated with crizotinib.Patients and Methods: A total of 82 patients with ALK-positive metastatic or non-resectable NSCLC who received ALK TKI crizotinib were included. Pre-treatment modified Glasgow prognostic score (mGPS), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII) were calculated. Multivariable logistic regression and Cox proportional hazards models were used to assess the impact of pretreatment mGPS, PNI, and SII on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).Results: The ORR was 77.2%, while 1-year OS and PFS rates were 95.0% and 93.5%, respectively. The univariate analysis revealed significantly higher 1-year PFS (89.4 vs. 64.4%, p=0.043) and OS (92.0 vs. 83.3%, p=0.01) rates in patients with low (<934.7) vs. high (>= 934.7) SII scores. Multivariate analysis revealed that PNI >= 0.09 was a significant determinant of poorer 1-year OS rates (hazard ratio [HR]: 2.46, 95% confidence interval [CI] 0.88-4.85, p=0.035). No significant difference was observed in survival rates according to gender, age, smoking status, prior lines of therapy, or mGPS scores, while higher mGPS scores (odds ratio [OR]: 0.1, 95%CI 0.16-1.04; p=0.009) and higher PNI scores (OR: 0.16, 95% CI 0.02-0.55; p=0.035) were associated with poorer ORR.Conclusion: Our findings indicate the prognostic significance of PNI and SII in terms of survival outcome and the impact of mGPS and PNI on treatment response in patients with ALK-positive NSCLC treated with crizotinib.